V. Fremeaux-bacchi, F. Fakhouri, A. Garnier, F. Bienaimé, M. A. Dragondurey et al., Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults, Clin J Am Soc Nephrol, vol.8, pp.554-562, 2013.

F. Fakhouri, Y. Delmas, F. Provot, C. Barbet, A. Karras et al., Frémeaux-Bacchi V: Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: An analysis of 19 cases, Am J Kidney Dis, vol.63, pp.40-48, 2014.

M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti et al., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin J Am Soc Nephrol, vol.5, pp.1844-1859, 2010.

C. M. Legendre, C. Licht, and C. Loirat, Eculizumab in atypical hemolyticuremic syndrome, N Engl J Med, vol.369, pp.1379-1380, 2013.

C. Licht, L. A. Greenbaum, P. Muus, S. Babu, C. L. Bedrosian et al., Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies, Kidney Int, vol.87, pp.1061-1073, 2015.

F. Fakhouri, M. Hourmant, J. M. Campistol, S. R. Cataland, M. Espinosa et al., Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: A single-arm, openlabel trial, Am J Kidney Dis, vol.68, pp.84-93, 2016.

C. Loirat, F. Fakhouri, G. Ariceta, N. Besbas, M. Bitzan et al., An international consensus approach to the management of atypical hemolytic uremic syndrome in children, Pediatr Nephrol, vol.31, pp.15-39, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02149335

L. A. Greenbaum, M. Fila, G. Ardissino, S. I. Al-akash, J. Evans et al., Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome, Kidney Int, vol.89, pp.701-711, 2016.

R. Cofiell, A. Kukreja, K. Bedard, Y. Yan, A. P. Mickle et al., Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS, Blood, vol.125, pp.3253-3262, 2015.

M. Noris, M. Galbusera, S. Gastoldi, P. Macor, F. Banterla et al., Dynamics of complement activation in aHUS and how to monitor eculizumab therapy, Blood, vol.124, pp.1715-1726, 2014.

A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers et al., Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation, Ann Intern Med, vol.130, pp.461-470, 1999.

G. J. Schwartz, A. Muñoz, M. F. Schneider, R. H. Mak, F. Kaskel et al., New equations to estimate GFR in children with CKD, J Am Soc Nephrol, vol.20, pp.629-637, 2009.

P. Vieira-martins, E. Sissy, C. Bordereau, P. Gruber, A. Rosain et al., Defining the genetics of thrombotic microangiopathies, Transfus Apheresis Sci, vol.54, pp.212-219, 2016.

F. Bienaime, M. A. Dragon-durey, C. H. Regnier, S. C. Nilsson, W. H. Kwan et al., FremeauxBacchi V: Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome, Kidney Int, vol.77, pp.339-349, 2010.

D. Kavanagh, Y. Yu, E. C. Schramm, M. Triebwasser, E. K. Wagner et al., Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels, Hum Mol Genet, vol.24, pp.3861-3870, 2015.

S. Hyvärinen, S. Meri, and T. S. Jokiranta, Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome, Blood, vol.127, pp.2701-2710, 2016.

S. Recalde, A. Tortajada, M. Subias, J. Anter, M. Blasco et al., Rodríguez de Có rdoba S: Molecular basis of factor H R1210C association with ocular and renal diseases, J Am Soc Nephrol, vol.27, pp.1305-1311, 2016.

J. P. Venables, L. Strain, D. Routledge, D. Bourn, H. M. Powell et al., Atypical haemolytic uraemic syndrome associated with a hybrid complement gene, J Immunol Methods, vol.3, pp.8-26, 2011.

E. C. Schramm, L. T. Roumenina, T. Rybkine, S. Chauvet, P. Vieiramartins et al., Fremeaux-Bacchi V: Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome, Blood, vol.125, pp.2359-2369, 2015.

G. Ardissino, S. Testa, I. Possenti, F. Tel, F. Paglialonga et al., Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: A report of 10 cases, Am J Kidney Dis, vol.64, pp.633-637, 2014.

G. Ardissino, I. Possenti, F. Tel, S. Testa, S. Salardi et al., Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: An update, Am J Kidney Dis, vol.66, pp.172-173, 2015.

N. S. Sheerin, D. Kavanagh, T. H. Goodship, and S. Johnson, A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience, QJM, vol.109, pp.27-33, 2016.

J. F. Wetzels and N. C. Van-de-kar, Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome, Am J Kidney Dis, vol.65, 2015.

J. Zuber, F. Fakhouri, and L. T. Roumenina,

, French Study Group for aHUS/C3G: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nat Rev Nephrol, vol.8, pp.643-657, 2012.